A Safety and Tolerability Study of Topical PAT-001 in Congenital Ichthyosis
Status:
Completed
Trial end date:
2018-12-04
Target enrollment:
Participant gender:
Summary
Congenital ichthyosis (CI) is a large, heterogeneous family of inherited skin disorders of
cornification resulting from an abnormality of skin keratinization, such as scaling and
thickening of the skin. Treatment options include keratolytic agents, which can abruptly lead
to extensive shedding or peeling of scales. PAT-001 primarily acts as a keratolytic agent;
thus, making it a potential drug candidate for the treatment of skin disorders associated
with hyperkeratinization, such as CI. The current study intends to evaluate the safety and
tolerability of PAT-001 in patients with CI of either the Lamellar or X-Linked subtypes.